Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Deloitte
Federal Trade Commission
Chinese Patent Office
Mallinckrodt
Moodys
Fuji
Cerilliant
Harvard Business School

Generated: April 20, 2018

DrugPatentWatch Database Preview

Dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir and what is the scope of dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir freedom to operate?

Dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
is the generic ingredient in one branded drug marketed by Abbvie Inc and is included in one NDA. There are eighteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir has five hundred and twenty-five patent family members in fifty-one countries.

One supplier is listed for this compound.
Summary for dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
International Patents:525
US Patents:18
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 3,222
Drug Prices:see low prices
DailyMed Link:dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir at DailyMed

US Patents and Regulatory Information for dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 ➤ Sign Up ➤ Sign Up
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,452,194 Methods for treating HCV ➤ Sign Up
8,332,661 Method and apparatus for prevention of tampering, unauthorized use, and unauthorized extraction of information from microdevices ➤ Sign Up
8,809,265 Methods for treating HCV ➤ Sign Up
9,043,925 Method and apparatus for prevention of tampering and unauthorized extraction of information from microdevices ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0150016 00154 Estonia ➤ Sign Up PRODUCT NAME: OMBITASVIIR;REG NO/DATE: EU/1/14/982 19.01.2015
2340029/01 Switzerland ➤ Sign Up PRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: SWISSMEDIC 65301 25.11.2014
2015013,C2203431 Lithuania ➤ Sign Up PRODUCT NAME: DASABUVIRAS; REGISTRATION NO/DATE: EU/1/14/983 20150115
2015 00014 Denmark ➤ Sign Up PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Farmers Insurance
UBS
Argus Health
US Army
Harvard Business School
Medtronic
McKesson
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.